Edition:
United States

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

24.00USD
18 Jan 2019
Change (% chg)

$1.63 (+7.29%)
Prev Close
$22.37
Open
$22.36
Day's High
$24.11
Day's Low
$21.66
Volume
745,355
Avg. Vol
775,013
52-wk High
$65.89
52-wk Low
$11.50

Latest Key Developments (Source: Significant Developments)

Armistice Capital Reports 9.8 Pct Stake In Clovis Oncology As Of Oct 24
Monday, 5 Nov 2018 05:37pm EST 

Nov 5 (Reuters) - Clovis Oncology Inc ::ARMISTICE CAPITAL, LLC REPORTS 9.8 PERCENT STAKE IN CLOVIS ONCOLOGY INC AS OF OCTOBER 24 - SEC FILING.ARMISTICE CAPITAL SAYS PURCHASED SHARES ON BELIEF CLOVIS ONCOLOGY'S SHARES, WHEN PURCHASED, WERE UNDERVALUED.  Full Article

Clovis Oncology Reports Q3 Loss Per Share Of $1.71
Tuesday, 30 Oct 2018 04:05pm EDT 

Oct 30 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2018 OPERATING RESULTS.Q3 LOSS PER SHARE $1.71.Q3 EARNINGS PER SHARE VIEW $-1.60 -- THOMSON REUTERS I/B/E/S.COMPANY ANTICIPATES Q4 2018 REVENUES TO BE CONSISTENT WITH OR SLIGHTLY HIGHER THAN Q3 2018.ANTICIPATES PROVIDING FULL-YEAR 2019 GUIDANCE IN EARLY JANUARY..  Full Article

Clovis Oncology Announces European Commission Authorization Of Rubraca
Tuesday, 29 May 2018 08:00am EDT 

May 29 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES EUROPEAN COMMISSION AUTHORIZATION OF RUBRACA® (RUCAPARIB) FOR WOMEN WITH RECURRENT OVARIAN CANCER.CLOVIS ONCOLOGY INC - EC APPROVAL WAS BASED ON DATA FROM TWO MULTICENTER, SINGLE-ARM, OPEN-LABEL CLINICAL TRIALS.  Full Article

Clovis Oncology Reports Q1 Loss Per Share $1.54
Tuesday, 8 May 2018 04:05pm EDT 

May 8 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS.Q1 LOSS PER SHARE $1.54.Q1 EARNINGS PER SHARE VIEW $-1.36 -- THOMSON REUTERS I/B/E/S.QTRLY PRODUCT REVENUE $18.5 MILLION VERSUS $7 MILLION.  Full Article

Clovis Oncology Says SEC Issued 'Wells Notices' To Co & Certain Of Its Officers
Tuesday, 10 Apr 2018 09:35am EDT 

April 10 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY SAYS ON APRIL 9 SEC ISSUED 'WELLS NOTICES' TO CO & CERTAIN OF ITS CURRENT AND FORMER OFFICERS - SEC FILING.SEC'S 'WELLS NOTICES' ALLEGES VIOLATIONS OF SOME PROVISIONS OF SECURITIES ACT OF 1933 AND SECURITIES EXCHANGE ACT OF 1934.ALLEGED VIOLATIONS RELATE TO CO'S REGULATORY UPDATE IN NOV 2015 THAT FDA REQUESTED MORE CLINICAL DATA ON EFFICACY, SAFETY OF ROCILETINIB.  Full Article

EMA Panel Recommends Conditional Approval Of Clovis Oncology Ovarian Cancer Drug Rubraca
Friday, 23 Mar 2018 08:52am EDT 

March 23 (Reuters) - EU Medicines Agency: :RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY <<>> OVARIAN CANCER DRUG RUBRACA.EU MEDICINES AGENCY SAYS RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR CLOVIS OVARIAN CANCER DRUG RUBRACA.  Full Article

Clovis Oncology Q4 Adjusted Loss Per Share $1.27
Monday, 26 Feb 2018 04:05pm EST 

Feb 26 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES 2017 OPERATING RESULTS.Q4 ADJUSTED LOSS PER SHARE $1.27 EXCLUDING ITEMS.Q4 LOSS PER SHARE $1.04.QTRLY ‍​NET PRODUCT REVENUE $17 MILLION VERSUS $78,000.Q4 REVENUE VIEW $20.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Clovis Oncology Receives Positive Trend Vote In European Regulatory Review Ovarian Cancer Treatment
Wednesday, 21 Feb 2018 05:10pm EST 

Feb 21 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY RECEIVES POSITIVE TREND VOTE FROM CHMP IN EUROPEAN REGULATORY REVIEW FOR RUCAPARIB OVARIAN CANCER TREATMENT INDICATION.CLOVIS ONCOLOGY INC - PENDING A POSITIVE RECOMMENDATION BY CHMP FOR RUCAPARIB TABLETS, FINAL APPROVAL BY EUROPEAN COMMISSION WOULD FOLLOW IN Q2 2018.  Full Article

Clovis Oncology reports Q3 adjusted shr loss of $1.24
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Clovis Oncology Inc -:CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS.Q3 ADJUSTED LOSS PER SHARE $1.24 EXCLUDING ITEMS.Q3 LOSS PER SHARE $1.24.Q3 EARNINGS PER SHARE VIEW $-1.22 -- THOMSON REUTERS I/B/E/S.  Full Article

Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet
Wednesday, 13 Sep 2017 06:00am EDT 

Sept 13 (Reuters) - Clovis Oncology Inc :Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet.Study successfully achieved primary, key secondary and exploratory endpoints​.Plans to submit supplemental new drug application in U.S. for maintenance treatment indication in ovarian cancer by end of Oct 2017​.In early 2018, plans to file MAA in Europe for maintenance treatment indication upon receipt of potential approval for treatment indication​.  Full Article

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.